Advertisement
Brief report| Volume 20, ISSUE 5, P573-575, May 1985

High-dose naloxone administration in chronic schizophrenia

  • Martin R. Cohen
    Correspondence
    Address reprint requests to Dr. Martin R. Cohen, Ensor Foundation Research Laboratory, William S. Hall Psychiatric Institute, PO Box 202, Columbia, SC 29202, USA.
    Affiliations
    From the Clinical Studies Section, Clinical Neuroscience Branch National Institute of Mental Health, Bethesda, MD, USA
    Search for articles by this author
  • David Pickar
    Affiliations
    From the Clinical Studies Section, Clinical Neuroscience Branch National Institute of Mental Health, Bethesda, MD, USA
    Search for articles by this author
  • Robert M. Cohen
    Affiliations
    Section on Brain Imaging, Laboratory of Psychology and Psychopathology, National Institute of Mental Health, Bethesda, MD, USA
    Search for articles by this author
DOI:https://doi.org/10.1016/0006-3223(85)90030-7
High-dose naloxone administration in chronic schizophrenia
Previous ArticleA study of the TRH test in a family with psychiatric illness: A reflection on the TRH test as a state-trait marker
Next ArticleLack of efficacy of estrogen supplementation to imipramine in resistant female depressives
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Bloom F.
        • Segal D.
        • Ling N.
        • Guillemin R.
        Endorphins: Profound behavioral effects in rats suggest new etiological factors in mental illness.
        Science. 1976; 194: 630-632
        • Cohen M.R.
        • Cohen R.M.
        • Pickar D.
        • Weingartner H.
        • Murphy D.L.
        High-dose naloxone infusions in normals.
        Arch Gen Psychiatry. 1983; 40: 613-619
        • Cohen M.R.
        • Cohen R.M.
        • Pickar D.
        • Sunderland T.
        • Muller E.
        • Murphy D.L.
        High-dose naloxone in depression.
        Biol Psychiatry. 1984; 19: 825-832
        • Davis G.C.
        • Bunney Jr, W.E.
        • DeFraites E.G.
        • Kleinman J.E.
        • Van Kammen D.P.
        • Post R.M.
        • Wyatt R.J.
        Intravenous naloxone administration in schizophrenia and affective illness.
        Science. 1978; 197: 74-77
        • Emrich H.M.
        • Cording C.
        • Piree S.
        • Kolling A.
        • von Zerseen D.
        • Herz A.
        Indication of an antipsychotic action of the opiate antagonist naloxone.
        Pharmakopsychiatr Neuropsychopharmakol. 1977; 10: 265-270
        • Gunne L.M.
        • Lindstrom L.
        • Terenius L.
        Naloxone-induced reversal of schizophrenic hallucinations.
        J Neural Transm. 1977; 40: 13-19
        • Jaffe J.H.
        • Martin W.R.
        Narcotic analgesics and antagonists.
        in: Goodman A.G. Goodman A.S. Gilman L. The Pharmacological Basis of Therapeutics. Macmillan, New York1980
        • Janowsky D.S.
        • Segal D.S.
        • Bloom F.
        • Abrams A.
        • Guillemin R.
        Lack of effect of naloxone on schizophrenic symptoms.
        Am J Psychiatry. 1977; 134: 926-927
        • Kurland A.A.
        • McCabe O.L.
        • Hanlon T.E.
        • Sullivan D.
        The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
        Am J Psychiatry. 1977; 134: 1408-1410
        • Lehman H.
        • Vasavan Niar N.P.
        • Kline N.S.
        Betaendorphin and naloxone in psychiatric patients: Clinical and biological effects.
        Am J Psychiatry. 1979; 136: 762-766
        • Pickar D.
        • Vartanian F.
        • Bunney W.
        • Maier H.P.
        • Gastpar M.T.
        • Prakash R.
        • Setti B.V.
        • Lideman R.
        • Belgaer B.
        • Sultalkousa M.
        • Sartorious N.
        Short-term naloxone administration in schizophrenic and manic patients.
        Arch Gen Psychiatry. 1982; 39: 313-319
        • Pickworth W.B.
        • Sharpe L.G.
        EEG-behavioral dissociation after morphine-like drugs in the dog: Further evidence for two opiate receptors.
        Neuropharmacology. 1979; 18: 617-622
        • Volavka J.
        • Mallya A.
        • Baig S.
        • Perez-Cruet J.
        Naloxone in chronic schizophrenia.
        Science. 1977; 196: 1227-1228
        • Watson S.J.
        • Berger P.A.
        • Akil H.
        • Mills M.J.
        • Barchas J.D.
        Effects of naloxone on schizophrenia: Reduction in hallucinations in a subpopulation of subjects.
        Science. 1978; 201: 73-76
        • Wood P.L.
        Multiple opiate receptors: Support for unique mu, delta, and kappa sites.
        Neuropharmacology. 1982; 21: 487-497

      Article info

      Publication history

      Received in revised form: November 20, 1984
      Received: October 16, 1984

      Identification

      DOI: https://doi.org/10.1016/0006-3223(85)90030-7

      Copyright

      © 1985 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX